Opponents of Kennedy's bid for top US health post urge senators to reject him

Published 01/24/2025, 06:06 AM
Updated 01/24/2025, 12:45 PM
© Reuters. FILE PHOTO: Robert Kennedy Jr., U.S. President-elect Donald Trump's nominee to run the Department of Health and Human Services, walks through the Russell Senate Office Building between meetings with senators on Capitol Hill in Washington, U.S., December 1

By Michael Erman and Stephanie Kelly

NEW YORK (Reuters) -More than 80 organizations voiced opposition on Friday to Robert F. Kennedy Jr's nomination to lead the top U.S. health agency ahead of his Senate confirmation hearing next week, while the group 314 Action (WA:ACT) launched a six-figure ad buy to influence Republican senators against him.

The $250,000 ad campaign will run across eight states in an effort to persuade Republican lawmakers - including Senators Mitch McConnell from Kentucky, Bill Cassidy from Louisiana and John Curtis from Utah - that Kennedy's past comments spreading misinformation on vaccines represents a danger to U.S. public health.

The senators will have the opportunity to question Kennedy about his nomination to lead the U.S. Health and Human Services Department at his hearing on Wednesday.

"Senators on both sides of the aisle have a responsibility to hold him accountable," said Shaughnessy Naughton, president of 314 Action, which aims to elect Democrats with a background in science to public office.

Meanwhile, consumer group Public Citizen and healthcare coverage advocacy group Protect Our Care co-wrote a letter sent on Friday to all 100 U.S. senators, urging them to announce their opposition to Kennedy. They recruited 85 other non-governmental groups to join the letter including the Union of Concerned Scientists, the NAACP and the National Organization for Women.

"If Robert F. Kennedy, Jr. takes command of the Department of Health and Human Services, we will face lies and disinformation at an unprecedented scale that are capable of unwinding a century of progress on fighting disease and promoting public health," the letter, seen by Reuters, said.

Republican President Donald Trump announced his choice of Kennedy in November for the position.

Most of the opposition to Kennedy is driven by his stance on vaccines, but a group founded by former Republican Vice President Mike Pence also objects to Kennedy's comments in support of abortion rights.

A spokesperson for Kennedy and the White House did not respond to requests for comment.

With Republicans holding a slim three-seat majority in the Senate, the party wants to ensure unity behind Kennedy, and no Republican senator has so far voiced opposition.

Kennedy has long sown doubts about the safety and efficacy of vaccines that have helped curb disease and prevent deaths for decades. He disputes the anti-vaccine characterization and has said he would not prevent Americans from getting inoculations.

But he has led the anti-vaccine group Children's Health Defense and in a 2023 interview with podcaster Lex Fridman, said no vaccines are safe and effective.

Kennedy has said he wants to work to end chronic disease, break any ties between employees at the U.S. drugs regulator and industry and advise U.S. water systems to remove fluoride.

© Reuters. FILE PHOTO: Robert Kennedy Jr., U.S. President-elect Donald Trump's nominee to run the Department of Health and Human Services, walks through the Russell Senate Office Building between meetings with senators on Capitol Hill in Washington, U.S., December 17, 2024. REUTERS/Benoit Tessier/File Photo

Kennedy has faced new scrutiny over his ties to Wisner Baum, a law firm specializing in pharmaceutical drug injury cases. Kennedy has an arrangement to earn 10% of fees awarded in contingency cases he refers to the firm, according to a letter Kennedy wrote to an HHS ethics official released on Wednesday.

If confirmed, Kennedy would retain that financial interest in cases that do not directly impact the U.S. government, the letter said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.